ECM
TCRT icon

ExodusPoint Capital Management’s Alaunos Therapeutics TCRT Stock Holding History

ExodusPoint Capital Management’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-203
Closed -$33K – 2675
2021
Q4 		$33K Buy
+203
New +$44.6K ﹤0.01% 2060
2021
Q3 		– Sell
-459
Closed -$182K – 2616
2021
Q2 		$182K Buy
+459
New +$214K ﹤0.01% 2018
2021
Q1 		– Sell
-139
Closed -$53K – 2593
2020
Q4 		$53K Buy
139
+68
+96% +$27K ﹤0.01% 1870
2020
Q3 		$27K Buy
+71
New +$31.4K ﹤0.01% 1663
2019
Q3 		– Sell
-131
Closed -$114K – 1638
2019
Q2 		$114K Buy
+131
New +$90.1K ﹤0.01% 1012

Other funds holding TCRT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

ExodusPoint Capital Management's TCRT Position: Q1 2022 in Review

ExodusPoint Capital Management sold out of Alaunos Therapeutics (TCRT) in Q1 2022, closing a stake of 203 shares — an estimated $33K sold.

ExodusPoint Capital Management first reported a position in TCRT in Q2 2019 and held it in 5 quarters. The position peaked at $182K in Q2 2021. 148 funds tracked by Wall St. Rank hold TCRT as of Q1 2022.

  • ExodusPoint Capital Management reported no remaining Alaunos Therapeutics position as of Q1 2022 after selling out during the quarter.
  • ExodusPoint Capital Management sold 203 Alaunos Therapeutics shares in Q1 2022, an estimated $33K.
  • ExodusPoint Capital Management first reported a position in Alaunos Therapeutics in Q2 2019 and held it in 5 quarters.
  • ExodusPoint Capital Management's Alaunos Therapeutics position peaked at $182K in Q2 2021.
  • 148 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2022.

Based on ExodusPoint Capital Management's 13F filing for Q1 2022, filed 13 May 2022.